DRRA

Fish Oil 2025: 43% Fewer Heart Events in Dialysis + No AFib Risk at Higher Omega-3 Levels

Fish Oil 2025: 43% Fewer Heart Events in Dialysis + No AFib Risk at Higher Omega-3 Levels

[ad_1] January 12, 2026 Table of Contents High-Dose Fish Oil Provides Strong Cardiovascular Protection in Dialysis Patients Why These Results Are Important Reframing Atrial Fibrillation Concerns: Focus on Blood Levels, Not Just Supplements What the Meta-Analysis Revealed Reconciling Benefits and Past Concerns of Omega-3 Supplementation in 2025 Implications for Heart Health in 2025 Conclusion Fish…

Read More
Phanes Therapeutics Reports P-II (TWINPEAK) Trial Data on Spevatamig + CT in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Phanes Therapeutics Reports P-II (TWINPEAK) Trial Data on Spevatamig + CT in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

[ad_1] Shots: The P-I/II (TWINPEAK) trial data assessed spevatamig alone & in combinations to treat advanced gastric, GEJ, pancreatic ductal or biliary tract adenocarcinomas in the US As of Dec 12, 2025, 107 pts received spevatamig alone or in combination; 42 with 1L mPDAC were treated with spevatamig + GnP, with spevatamig (2mg/kg, QW) data…

Read More
Enhancing Quality Through GDP Self-Inspections MVS Pharma GmbH

Enhancing Quality Through GDP Self-Inspections MVS Pharma GmbH

[ad_1] January 12, 2026 Table of Contents EU GDP Expectations for Self-Inspections Self-Inspection Program at MVS Pharma GmbH Qualified and Independent Execution Reporting and Classification of Findings CAPA Management and Follow-Up Management Review and Continuous Improvement Record Retention and Traceability Conclusion GDP Self-Inspections MVS Pharma GmbH overview: Self-inspections are a cornerstone of the EU Good…

Read More
Delhi HC allows student to continue MBBS

Delhi HC allows student to continue MBBS

[ad_1] Right to pursue higher education cannot be curtailed lightly: Delhi HC allows student to continue MBBS We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link

Read More